Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
GSK agreements with Hengrui Pharma to develop up to 12 innovative medicines
We are advising GSK on the transaction
Tempus AI $750 million convertible senior notes offering
The 0.75% convertible senior notes are due 2030
Adagene $25 million strategic equity investment from Sanofi
We advised Adagene on the transaction
Medtide HK$411.2 million IPO
We advised Medtide on its IPO and HKEX listing
Mirxes Holding Company HK$1.09 billion IPO
We advised Mirxes on its IPO and HKEX listing
ADC Therapeutics $100 million private placement
We advised ADC Therapeutics on the equity offering
Omada Health $172.6 million IPO
The shares are listed on the Nasdaq Global Select Market
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Hinge Health $503 million IPO
The shares are listed on the New York Stock Exchange
Kenvue $750 million senior notes offering
The investment-grade notes are due 2032